Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis.

By R. Moucari, T. Asselah, D. Cazals‐Hatem, H. Voitot, N. Boyer, M. Ripault, R. Sobesky, M. Martinot-Peignoux, S. Maylin, M. Nicolas-Chanoine and 5 more. Gastroenterology, 2008

608 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/c53ffe41cf5f8e4223b1c5cb89cf6797792290fa

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. C. Day
2. S. Bellentani

In Epidemiology

1. C. Day
2. S. Bellentani
3. V. Ratziu
4. H. Cortez‐Pinto
5. Giulio Marchesini

In Hepatology

1. C. Day
2. S. Bellentani

Citations in the corpus

• A position statement on NAFLD/NASH based on the EASL 2009 special conference. (2010, background): “NASH can occur together with other chronic liver diseases and that in some cases (chronic hepatitis C [4], hemochromatosis [5], alcoholic liver disease [6]) this can exacerbate liver damage [7].”
• Hepatitis C Guidance 2019 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection (2019, background): “(61,63,64,66-72) Similarly, counsel appropriately aged, untreated pediatric patients and their parents about the importance of maintaining a healthy body weight due to the deleterious effects of insulin resistance on HCV-related fibrosis progression.(260-271) WHoM aND WHeN to tReat aMoNg CHIlDReN aN”